Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
|Slideshows|July 11, 2019
Monthly Health Quiz: Effective Biologics, Inherited Conditions, Sexual Health
In this month's health quiz, we revisit some of our most popular articles published in recent weeks. This includes news reports on the safety and efficacy of baricitinib, upadacitinib effectiveness as monotherapy, inherited rheumatoid arthritis and our most popular story from this month: The sexual health of patients with musculoskeletal conditions.
Advertisement
In this month's health quiz, we revisit some of our most popular articles published in recent weeks. This includes news reports on the safety and efficacy of baricitinib, upadacitinib effectiveness as monotherapy, inherited rheumatoid arthritis and our most popular story from this month: The sexual health of patients with musculoskeletal conditions.
Advertisement
Related to this article
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.
A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.
Advertisement
Advertisement